Physiologically‐Based Pharmacokinetic Modeling Characterizes the CYP3A‐Mediated Drug‐Drug Interaction Between Fluconazole and Sildenafil in InfantsSara Salerno, Daniel González, Andrea N. Edginton et al.|Clinical Pharmacology & Therapeutics|2020Cited by 40
Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological ConsiderationsJacqueline G. Gerhart, Daniel González, Stephen J. Balevic et al.|Frontiers in Pharmacology|2022Cited by 40
The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology GroupRyan J. Beechinor, Daniel González, Patrick A. Thompson et al.|Clinical Pharmacokinetics|2019Cited by 39
Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic ModelingJacqueline G. Gerhart, Robert H. Lurie, Eliana M. Perrin et al.|Clinical Pharmacokinetics|2021Cited by 39
Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term InfantsSamit Ganguly, Andrea N. Edginton, Jacqueline G. Gerhart et al.|Clinical Pharmacokinetics|2021Cited by 33